Origin of Alzheimer Brain Plaques Studied
Posted on: Thursday, 10 April 2008, 15:01 CDT
U.S. researchers say they've found a nerve cell's normal intake and communication processes are essential to the production of Alzheimer's brain plaques.
The Washington University School of Medicine researchers in St. Louis said such plaques are accumulations of fragments of amyloid beta protein, and are found in post-mortem examinations of the brains of Alzheimer's patients.
Neuroscientists at the school experimentally manipulated the ability of brain cells to take in substances from their surface -- a process called endycytosis. To mice having a disease similar to Alzheimer's, the researchers administered a drug that stops the process of endocytosis. The result was a 70 percent reduction in the production of amyloid beta protein.
In another experiment, the researchers gave the mice a drug that reduced brain cell communication, but did not affect endocytosis. The result was a 60 percent reduction in amyloid beta production.
Blocking endocytosis isn't a viable option for treatment because cells throughout the body, including brain cells, need endocytosis for healthy function, said John Cirrito, a research instructor and first author of the study. But we are starting to understand the origins of amyloid beta in more detail now &133;
The study appears in the journal Neuron.
Source: United Press International
Related Articles
- New Brain Receptor, Possible Target For Alzheimer's Treatment Found
- Phase 3 Alzheimer's Drug Increases Toxic Beta Amyloid In The Brain Cut Can Still Provides Benefits
- A Phase III Alzheimer's Drug Increases Levels of Beta Amyloid in the Brain - But Still Provides Benefits
- The Neuchatel Institute of Microengineering (IMT) of EPFL and BrightView Systems Announce Collaboration for Solar Cell Production Process Optimization Solutions
- Sales of Stem Cell Products Expected to Surpass $35 Million in 2007, Leading Medical Industry Analyst Says
- Spire Offers 25 Megawatt Turnkey Solar Cell Production Line
- Cytori Therapeutics Names John Ransom, Ph.D., Vice President of Research, Regenerative Cell Technology
- High Insulin Levels Increase Inflammatory Markers and Beta-amyloids, May Contribute to Alzheimer's
- Affymax Presents Preclinical Data Demonstrating Hematide's(TM) Effect on Red Blood Cell Production and Prolonged Half Life
- Vasogen's VP025 Prevents Detrimental Effects of Beta-Amyloid in Preclinical Model of Cognitive Dysfunction
 |
 |
User Comments (0)
RSS Feeds